Warning Signals of Post-Exertional Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Retrospective Analysis of 197 Patients.
myalgic encephalomyelitis/chronic fatigue syndrome
post-exertional malaise
prevention
warning signal
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 Jun 2021
07 Jun 2021
Historique:
received:
24
03
2021
revised:
20
05
2021
accepted:
04
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Post-exertional malaise (PEM), the key feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is characterized by baseline symptom exacerbation after exposure to a stressor, and some patients can experience new or non-typical symptoms. We hypothesized that new or non-typical symptoms occurring long enough before onset of baseline symptom exacerbation could be warning signals predicting PEM. Adult ME/CFS patients who attended the internal medicine department of Angers University Hospital (France) between October 2011 and December 2019 were included in a retrospective medical records review. Patients who experienced one or more new or non-typical symptoms before baseline symptom exacerbation were compared with the rest of the study population for PEM features, epidemiological characteristics, fatigue features, and comorbidities. New or non-typical symptoms preceded baseline symptom exacerbation in 27/197 (13.7%) patients, and the most frequent ones were mood disorders (37%). When compared to the rest of the study population, only PEM intensity was significantly lower in these patients (
Identifiants
pubmed: 34200126
pii: jcm10112517
doi: 10.3390/jcm10112517
pmc: PMC8201170
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Brain Behav Immun. 2017 May;62:87-99
pubmed: 28216087
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
J Intern Med. 2010 Sep;268(3):265-78
pubmed: 20412374
BMJ Open. 2014 Nov 26;4(11):e005798
pubmed: 25428629
Expert Rev Neurother. 2010 Aug;10(8):1347-59
pubmed: 20662758
Psychol Med. 2011 Aug;41(8):1567-77
pubmed: 20836910
PLoS One. 2018 Jun 1;13(6):e0197811
pubmed: 29856774
Mol Psychiatry. 2003 Sep;8(9):773-85
pubmed: 12931205
Popul Health Metr. 2005 Jul 22;3:8
pubmed: 16042777
Am Heart J. 2008 Dec;156(6):1210-1216.e1
pubmed: 19033022
Psychosom Med. 2002 Mar-Apr;64(2):319-27
pubmed: 11914449
Int J Clin Exp Med. 2009;2(1):1-16
pubmed: 19436827
PLoS One. 2015 Dec 18;10(12):e0145453
pubmed: 26683192
Int J MS Care. 2013 Spring;15(1):15-20
pubmed: 24453758
BMC Fam Pract. 2017 May 5;18(1):60
pubmed: 28476151
Lancet. 2006 Jan 28;367(9507):346-55
pubmed: 16443043
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
BMJ. 1995 Aug 26;311(7004):544-5
pubmed: 7663210
Headache. 2004 Oct;44(9):865-72
pubmed: 15447695
Diagnostics (Basel). 2019 Mar 02;9(1):
pubmed: 30832336
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):784-94
pubmed: 20609377
BMC Med. 2013 Sep 17;11:205
pubmed: 24229326
Am J Psychiatry. 1991 Jul;148(7):823-30
pubmed: 2053620
Front Immunol. 2018 Feb 15;9:229
pubmed: 29497420
Curr Neuropharmacol. 2015;13(5):701-34
pubmed: 26411464
World J Methodol. 2015 Jun 26;5(2):68-87
pubmed: 26140274
Sci Rep. 2019 Dec 11;9(1):18817
pubmed: 31827223
Ann Intern Med. 2016 Jan 5;164(1):23-9
pubmed: 26720493
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991